Better Therapeutics(OTC) BTTX

Market Cap$5.40K

Since IPO (2021)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0%

+0.00Today

Better Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-29

Better Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-17
1 month	+0%	USD 0.00	2026-06-26
3 month	+0%	USD 0.00	2026-04-30
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-07-28
3 year	-99.98%	USD 0.62	2023-07-28
5 year	-100%	USD 9.93	2021-07-30
Since inception	-100%	USD 10.00	2021-03-17

Better Therapeutics Financials at a Glance

Market Cap

$5.40K

Revenue (TTM)

$0.00

Net Income (TTM)

-$31.57M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-17.08 (Low)

Dividend

$0.00

Beta (Volatility)

-17.08 (Low)

Price

$0.00

Volume

164

Open

$0.00

Price

$0.00

Volume

164

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

May 29, 2026

Dividend

$0.00

Beta (Volatility)

-17.08 (Low)

Price

$0.00

Volume

164

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

May 29, 2026

BTTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Better Therapeutics

Better Therapeutics, Inc. is a prescription digital therapeutics company focused on developing cognitive behavioral therapy solutions to address cardiometabolic diseases. The company’s lead product candidate, BT-001, targets type 2 diabetes, while its pipeline includes therapies for hypertension, hyperlipidemia, and chronic kidney disease.

Products and Services

BT-001: Investigational platform for type 2 diabetes treatment
BT-002: Aims to improve glycemic control for hypertension
BT-003: Targets LDL cholesterol reduction in hyperlipidemia patients

Growth Outlook

Strong focus on digital therapeutics aligns with healthcare trends
Potential market expansion as cardiometabolic diseases rise globally
Innovative product pipeline may attract strategic partnerships

Financial Highlights

Q3 2023 net income of -$5.86 million, reflecting ongoing investment in R&D
Cash and cash equivalents increased to $6.6 million by Q3 2023
Operating expenses totaled $5.34 million in Q3 2023, indicating cost management efforts

Better Therapeutics, Inc. operates in the biotechnology sector, emphasizing the development of software-based solutions for chronic health conditions. The company has made significant investments in research and development, which is reflected in its recent financials. Despite reporting a net loss, the increase in cash reserves suggests a strategic focus on sustaining operations and advancing product development. The innovative approach to treating cardiometabolic diseases positions Better Therapeutics favorably within a growing market, potentially leading to future growth and partnership opportunities.

AI Generated • Jul 24, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

CEO

Frank L. Karbe, MBA

Website

www.bettertx.com

Headquarters

San Francisco, CA 94104, US

BTTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-221.99%

Return on Capital

-273.67%

Return on Assets

-173.30%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.40K

Shares Outstanding

54.35M

Volume

164

Avg. Volume

4.31K

Financials (TTM)

Gross Profit

-$1.64M

Operating Income

-$29.61M

EBITDA

-$26.50M

Operating Cash Flow

-$26.08M

Capital Expenditure

-$1.39M

Free Cash Flow

-$27.47M

Cash & ST Invst.

$6.60M

Total Debt

$14.31M

Better Therapeutics Performance Analysis

Better Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 0	N/A
2022	2022-12-31	USD 0	N/A

Better Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	N/A
Q1	2023-03-31	N/A
Q2	2023-06-30	N/A
Q3	2023-09-30	N/A

Better Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -1.71	N/A
2022	2022-12-31	USD -1.69	-1.2%

Better Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2022-12-31	22.9%
Q1	2023-03-31	-5.4%
Q2	2023-06-30	38.5%
Q3	2023-09-30	37.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$841.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.40K

N/A

Market Cap/Employee

$100.00

N/A

Employees

N/A

Net Income

-$5.86M

+48.6%

EBITDA

-$4.50M

+56.3%

Quarterly Fundamentals

Name

Q3 2023YOY CHG

Total Cash

$6.60M

-70.4%

Total Debt

$14.31M

-3.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.72M

-33.8%

Short Term Debt

$6.59M

+110.5%

Return on Assets

-1.73%

N/A

Return on Invested Capital

-4.05%

N/A

Free Cash Flow

-$5.95M

+19.5%

Operating Cash Flow

-$5.94M

+15.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PANCPanacos Pharmaceuticals, Inc.

PANCPanacos Pharmaceuticals, Inc.$0.00+0.00%

ARNIArno Therapeutics, Inc.

ARNIArno Therapeutics, Inc.$0.00+0.00%

SCIESpectraScience, Inc.

SCIESpectraScience, Inc.$0.00+0.00%

BXRXQBaudax Bio, Inc.

BXRXQBaudax Bio, Inc.$0.00+0.00%

KLDOKaleido Biosciences, Inc.

KLDOKaleido Biosciences, Inc.$0.00+0.00%

UPPRUpper Street Marketing Inc.

UPPRUpper Street Marketing Inc.$0.00+0.00%

CALACalithera Biosciences, Inc.

CALACalithera Biosciences, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About BTTX

What is the current price of Better Therapeutics?

Better Therapeutics is trading at $0.00 per share.

What is the 52-week range for Better Therapeutics?

Over the past 52 weeks, Better Therapeutics has traded between $0.00 and $0.00.

How much debt does Better Therapeutics have?

As of the most recent reporting period, Better Therapeutics reported total debt of $14.88M.

How much cash does Better Therapeutics have on hand?

Better Therapeutics reported $15.74M in cash and cash equivalents in its most recent financial results.

What is Better Therapeutics’s dividend yield?

Better Therapeutics does not currently have a dividend yield.

Better Therapeutics(OTC) BTTX

Better Therapeutics Financials at a Glance

BTTX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Better Therapeutics

BTTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Better Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BTTX

What is the current price of Better Therapeutics?

What is the 52-week range for Better Therapeutics?

How much debt does Better Therapeutics have?

How much cash does Better Therapeutics have on hand?

What is Better Therapeutics’s dividend yield?

Premium Investing Services